Top Tweets for #AVACOPAN
#Rituximab With or Without #Avacopan in #ANCA-Associated Vasculitis With Severe Renal Involvement
#VisualAbstract by @assad_sm
https://t.co/WwA9KHftrh
The recent discussions surrounding #avacopan are an important reminder that concerns about trial conduct should not automatically be conflated with the biological effects of a therapy. Science advances by questioning, validating, and replicating https://t.co/HkUeATIasI
Australia joins a growing list of regulators scrutinizing avacopan's benefit-risk profile. Should ANCA vasculitis patients be concerned? @Amgen's Tavneos is now under TGA review. https://t.co/QPdM3mSGxt #Tavneos #avacopan #ThePharmaLetter #DrugSafety
📢 @LCalabreseDO discussed recent coverage regarding the FDA’s effort to revoke its approval of #avacopan for ANCA-associated vasculitis.
“This is really important,” he said.
See the full video here 👇
https://t.co/EFBO2VdYQM
NEJM retracts a trial 📑 that informed the 2021 regulatory approval of #Avacopan for treatment of ANCA vasculitis
Select clinical events were re-adjudicated following initial database lock & sponsor unblinding —> reanalysis turned neutral results +ve
1/
https://t.co/UKP3D1M1aD
💊 #Avacopan safety in #AAV — real-world data
FAERS analysis (n=3150 AEs):
➡️ Overall favourable safety profile
➡️ ⚠️ Hepatobiliary events most frequent
➡️ Higher AE risk in ≥65 yrs & females
➡️ Median onset ~48 days
📌 Supports risk-informed monitoring in clinical practice
🔗 https://t.co/mVEdkyayOx
#Vasculitis #Rheumatology #DrugSafety #RealWorldEvidence
Systematic Review of Efficacy and Safety of #Avacopan in #RealWorld Clinical Practice
#VisualAbstract by @Cteodosiu
https://t.co/oYPe8WdoZT
In a recent study regarding outcomes among patients with granulomatosis with polyangiitis (#GPA) and microscopic polyangiitis (#MPA) on #Avacopan published in #AnnalsOfTheRheumaticDiseases, Brian Jaros, MD (@Dr_Brian_MD), Anisha Dua, MD (@anisha_dua), and colleagues share important insights from their findings. https://t.co/SmVVspwLMH
The phase 3 ADVOCATE trial demonstrates that blocking the alternative complement pathway with #avacopan, alongside standard #immunosuppression, allows patients with #ANCA-associated #vasculitis (AAV) to substantially reduce #glucocorticoid (GC) exposure while maintaining equivalent efficacy and safety. Subgroup analyses confirm consistent benefits across diverse patient profiles—including varied organ involvement, disease severity, and age groups—with particularly pronounced advantages in those with #renal impairment, #pulmonary manifestations, or relapsing disease.
Real-world post-approval data reinforce these results, revealing sustained remission rates >70% at 12 months in avacopan-treated cohorts and a ~50% decrease in GC-associated adverse events versus historical benchmarks. Extended follow-up highlights enhanced renal survival in severe glomerulonephritis cases, with markedly lower rates of progression to end-stage kidney disease. The convenience of oral dosing improves adherence and quality of life by eliminating infusion requirements. Active trials are evaluating avacopan in pediatric AAV and synergistic combinations with emerging biologics, which may broaden its therapeutic scope. Current guidelines endorse avacopan as a preferred GC-sparing strategy for new-onset or relapsing AAV, ushering in an era of targeted complement inhibition for vasculitis care.
*de Groot K. Targeting the complement system in ANCA-associated vasculitis management.Rheumatology (Oxford), 2025.
🔗https://t.co/uYFWsAHNPK
#Avacopan or #Glucocorticoids for Severe Antineutrophil Cytoplasmic Autoantibody–Associated Rapidly Progressive #Glomerulonephritis #ANCA
#VisualAbstract by @priti899
https://t.co/3id035NpUb
Treatment With #Avacopan in #ANCA Associated #Vasculitis With Kidney Involvement
#VisualAbstract by @deniise_am
https://t.co/KbGGzhxO71
OP0171 #EULAR2025 Post-marketing surveillance of #Avacopan in Japan
🔹n= 401 MPA/GPA patients:
✔️75.8% in remission at 6 months
⚠️49% had AEs, hepatotoxicity in 19.6% (serious 4.5%) genetic factor ?
💊 Drug retention: 74.3%
👉 Effective, but close liver monitoring is important.
Excellent update today at #BSR25 on ANCA #vasculitis by @KSunmboye chaired by @chriswincup
Pathogenesis, immunology and treatment #AAV #Avacopan
🎙️In this episode of A Pinch of Salt, we explore the role of Avacopan in ANCA-Associated Vasculitis. Lorraine Harper from the University of Birmingham shares insights on pathophysiology, current therapies, and future treatment possibilities.
🔗 3 episodes are now available on Apple Podcast, Spotify, YouTube, Amazon Music, and more!
🎧 Hit play now 👉 https://t.co/5jw2g95C1j
@RickABright @cbarbermd @FortuneMagazine @angie_rasmussen @DebbyvanRiel @scotthensley @Lakdawala_Lab Karen is a pro and “Wheels of Change” has impacted so many. A+
#vilobelimab is highly specific yet doesn’t inhibit downstream immune responses. Prevention is key - tx ignored bc ppl challenged to think 3-4 steps ahead.
#Avacopan #tolilizumab
$AMGN $IFRX $RHHBY
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.6M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.9M followers
Taylor Swift
@taylorswift13
83.8M followers
Lady Gaga
@ladygaga
75.3M followers
Virat Kohli
@imvkohli
73.1M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.2M followers
Bill Gates
@billgates
65M followers
Selena Gomez
@selenagomez
62.9M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers